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Abstract
Background: It is challenging to engage repeat users of unscheduled healthcare with severe health anxiety in
psychological help and high service costs are incurred. We investigated whether clinical and economic outcomes
were improved by offering remote cognitive behaviour therapy (RCBT) using videoconferencing or telephone
compared to treatment as usual (TAU).
Methods: A single-blind, parallel group, multicentre randomised controlled trial was undertaken in primary and
general hospital care. Participants were aged ≥18 years with ≥2 unscheduled healthcare contacts within 12 months
and scored >18 on the Health Anxiety Inventory. Randomisation to RCBT or TAU was stratified by site, with
allocation conveyed to a trial administrator, research assessors masked to outcome. Data were collected at baseline,
3, 6, 9 and 12 months. The primary outcome was change in HAI score from baseline to six months on an intention-
to-treat basis. Secondary outcomes were generalised anxiety, depression, physical symptoms, function and overall
health. Health economics analysis was conducted from a health service and societal perspective.
Results: Of the 524 patients who were referred and assessed for trial eligibility, 470 were eligible and 156 (33%)
were recruited; 78 were randomised to TAU and 78 to RCBT. Compared to TAU, RCBT significantly reduced health
anxiety at six months, maintained to 9 and 12 months (mean change difference HAI –2.81; 95% CI –5.11 to –0.50; P
= 0.017). Generalised anxiety, depression and overall health was significantly improved at 12 months, but there was
no significant change in physical symptoms or function. RCBT was strictly dominant with a net monetary benefit of
£3,164 per participant at a willingness to pay threshold of £30,000. No treatment-related adverse events were
reported in either group.
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Conclusions: RCBT may reduce health anxiety, general anxiety and depression and improve overall health, with
considerable reductions in health and informal care costs in repeat users of unscheduled care with severe health
anxiety who have previously been difficult to engage in psychological treatment. RCBT may be an easy-to-
implement intervention to improve clinical outcome and save costs in one group of repeat users of unscheduled
care.
Trial registration: The trial was registered at ClinicalTrials.gov on 19 Nov 2014 with reference number NCT02298036
Keywords: Illness anxiety disorder, Hypochondriasis, Depression, High care costs, Urgent care, Family care, Cognitive
behaviour therapy, Digital, Videoconferencing, Remote therapy
Introduction
In health services, unscheduled same-day care is defined as
any unplanned contact with a health service by a person re-
quiring or seeking help, care or advice [1]. Globally, un-
scheduled same-day care is increasing across primary and
hospital care settings, presenting a burgeoning challenge
for health systems [2–4]. Severe health anxiety, which is de-
fined as a preoccupation with health worries or a belief that
one might have a serious physical illness [5], is one possible
reason for repeated use of unscheduled care. Severe health
anxiety is a common feature of healthcare, with a lifetime
prevalence of 8.5% in primary care and 24% in hospital
clinics [6, 7]. Severe health anxiety can lead to increased
unscheduled care use for reassurance and increased med-
ical investigations, or delayed healthcare attendance
followed by catastrophic emergency presentation because
of anxiety-related healthcare avoidance. It may increase
people’s functional impairment, sickness absence, risk of
cardiovascular disease and other chronic physical or mental
health problems and increase healthcare costs [8–10].
Cognitive behaviour therapy (CBT) is a well-evidenced
treatment for severe health anxiety, with benefits lasting
at least five years [11–13]. Despite the effectiveness of
CBT for health anxiety, uptake is typically low because
of stigma and negative experiences of mental health ser-
vices [14, 15]. Remotely delivered CBT (RCBT), whereby
patients talk directly to a CBT therapist using
internet-based videoconferencing and/or the telephone,
may enhance accessibility, acceptability and service cap-
acity for patients with severe health anxiety. For anxiety
and somatic disorders, RCBT can achieve comparable
outcomes to face-to-face treatment [16, 17]. Digitally de-
livered psychological therapies are generally more effect-
ive when supported by a therapist, as opposed to being
unguided or self-guided [18, 19]. Therefore, use of a
therapist via the phone or online might maintain the ef-
ficacy of CBT for health anxiety. Furthermore, remote
delivery may improve access for those who are con-
cerned about using mental health services, live in rural
areas with reduced access to services, travel frequently
or are restricted by comorbid health conditions, family
care or work commitments.
The rationale for this study was that if repeat users of
unscheduled care with severe health anxiety could be eas-
ily identified in routine healthcare settings by health pro-
fessionals with whom they already have an established
relationship, then an acceptable explanation of their prob-
lems might be facilitated through a trusted source. Offer-
ing RCBT in an accessible format, via videoconferencing
or telephone, may then enable participants to become en-
gaged with treatment more easily. We used a model of
CBT that previously showed sustained reductions in
health anxiety over five years [11], but delivered it re-
motely to a targeted high service-use population. For
health anxiety, CBT promotes self-management tech-
niques that may sustainably improve health anxiety. This
may reduce the need to seek reassurance from health pro-
fessionals and informal carers, or more timely care for ser-
ious health problems may be sought, reducing the need
for emergency in-patient care. In turn, health and informal
care costs might be reduced.
The primary aim of this study was to assess the clinical
and economic outcomes of RCBT via videoconferencing
or telephone to repeat users of unscheduled care with
severe health anxiety compared to usual care.
Methods
Study design and participants
We conducted a single-blind, patient-level, parallel group,
multicentre randomised controlled trial (RCT) in primary
and secondary care centres across the East Midlands and at
two other English sites. Participants were recruited from
emergency departments, walk-in centres, hospital out-
patient clinics and GP practices offering same-day appoint-
ments. Participants were approached if they were aged 18
years and over; had two or more unscheduled consultations
with any healthcare provider in the last 12 months, not at-
tributed to identified pathology; met criteria for clinical se-
verity of health anxiety (a score of 18 or above on the
14-item Short Health Anxiety Inventory, SHAI [20, 21])
and had sufficient understanding of English to engage with
the intervention. A SHAI score ≥18 is the clinical cut-off
used by Improving Access to Psychological Therapies in
the UK to identify patients who meet the diagnostic criteria
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for hypochondriasis/severe health anxiety. Patients were ex-
cluded if they were at immediate risk of harm to themselves
or others; had moderate to severe learning disability; a ser-
ious mental or physical illness, including substance use dis-
order, to the extent that engagement in the intervention
would not be possible, e.g. communication difficulties; were
receiving ongoing investigations for a pathological medical
condition; or had received specialist mental health interven-
tion within the previous six months. We intentionally in-
cluded those diagnosed with chronic physical conditions or
common mental health problems. The trial protocol is pub-
lished [22].
Randomisation and masking
Randomisation was determined by a computer-generated
pseudo-random code using random permuted blocks of 2,
4 or 6, created by the Nottingham Clinical Trials Unit in
accordance with their standard operating procedure and
held on a secure server. Participants were allocated with
equal probability (1:1) to each treatment arm, with stratifi-
cation by site. The administration officer relayed treat-
ment allocation information to CBT therapists and
participants. Only the trial manager and the administra-
tion support officer had password access to the
un-blinded randomisation data. The researchers respon-
sible for collecting the baseline and outcome data were
blind to randomisation until collection of all data was
complete. Any instances of un-blinding were recorded.
Procedures
The principles of user-design and co-production were
utilised by developing a network of patient and public
involvement (PPI) members, health practitioners and re-
searchers contributing at all stages of the study including
study design, recruitment, RCBT delivery methods and
interpretation of results [23]. In particular, iterative feed-
back with this network of practice and the experience of
PPI members meant we could develop and use engaging,
non-stigmatising explanations in study procedures and
materials and adopt simple, flexible procedures to iden-
tify, recruit and retain patients.
Referring clinicians approached patients meeting eligi-
bility criteria and sought consent for them to be contacted
by study researchers. Referrers explained to patients that
the aim of the study was to find out whether talking to a
health professional via videoconferencing or telephone
might help them to cope better with distress linked to
their bodily symptoms. Most practitioners approached pa-
tients opportunistically during usual care consultations,
based on their clinical knowledge of the patient. They also
used electronic administrative prompts on patient medical
notes, which highlighted repeat users of urgent ‘same-day’
appointments. Some practitioners posted study invitation
letters to patients who might meet the study criteria after
electronically searching patient records. One primary care
centre sent out text messages to such patients.
A researcher telephoned potential participants who
provided written or verbal consent. The researcher ex-
plained they had been referred to the study because they
had been experiencing physical symptoms and associ-
ated distress and that talking therapy via videoconferenc-
ing or telephone may help to manage distress.
Participants were informed they had a 1 in 2 chance of
receiving the RCBT intervention and that the study was
being offered as an additional source of support, rather
than replacing or restricting their current healthcare use.
No participant was told that an aim of the study was to
reduce service use. Further study information was
posted to all participants prior to a baseline assessment
interview, which was arranged at a time and place suit-
able for the patient. Verbal and written consent was re-
ceived at this baseline assessment interview. Following
assessment and confirmation of eligibility, participants
were randomly allocated to one of two treatment arms:
RCBT in addition to usual treatment, or treatment as
usual (TAU).
Remote cognitive behaviour therapy (RCBT)
Participants allocated to the RCBT arm were provided
with a detailed information sheet about RCBT, an RCBT
guide, a manual to help set up the videoconferencing sys-
tem (where used) and a contingency management plan for
when connection was poor or not possible. A CBT therap-
ist contacted participants within 10 days of randomisation.
A team of four experienced CBT therapists remotely de-
livered CBT for health anxiety using a treatment manual
developed from the Cognitive Behavioural Therapy for
Health Anxiety in Medical Patients (CHAMP) study [15].
Between six and 12 sessions of CBT were offered, with up
to three booster sessions if required. This included an ini-
tial ‘setup’ session, during which the methods used to
adapt CBT to remote delivery were discussed and any
concerns about this method were addressed. The number
of sessions offered depended on treatment response: more
sessions were offered when treatment response was
slower. Treatment used CBT principles to assess and test
beliefs about health, illness and associated issues that were
likely to be causing distress. Behavioural strategies known
to maintain health anxiety were identified and collabora-
tively reduced or stopped (Additional file 1: Table S1). Par-
ticipants also received text messages/email reminders
about their CBT sessions. Participants were free to con-
tinue to consult their usual healthcare providers other
than the CBT therapist throughout the intervention and
after treatment completion.
RCBT was delivered via a videoconferencing system
called WebEx or by telephone, depending on the partici-
pant’s preference. WebEx was selected because of
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connection security and interactive utilities enabling an
experience close to face-to-face CBT. At the time of as-
sessment, compared to nine other piloted systems, WebEx
was also comparatively cheaper. Permission was sought to
record audio/video during treatment sessions. These were
accessible to participants as a means of consolidating
learning from each session.
Recordings were also used for assessment and im-
provement of therapeutic quality in the clinical supervi-
sion of CBT therapists. Group clinical supervision was
conducted monthly via WebEx. Audio/video recordings
of the most recent sessions with patients who were not
responding to treatment were reviewed and appropriate
treatment approaches were discussed. The lead therapist
from the CHAMP trial (HT) conducted clinical over-
sight [11]. A version of the Cognitive Therapy Rating
Scale Revised (CTSR) [24], adapted to health anxiety,
was used for two randomly selected sessions given by
each therapist at four time points to assess, maintain
and improve therapist competence and treatment fidel-
ity. In this way, remote delivery meant that a few thera-
pists could be used to consistently deliver the
intervention over a large geographical area.
Treatment as usual (TAU)
Usual care included informing the participant, their GP
and any other healthcare referrer of the participant’s in-
volvement in the study. For participants whose baseline
assessment scores suggested risk of harm to themselves
or others, or if they required a referral to a different ser-
vice, a phone call was made and a letter sent to referrers
including to deliver information regarding the patient’s
severity of health anxiety, risk of harm, other comorbidi-
ties and their quality of life. Treatment as usual was
unconstrained.
Outcomes
The primary clinical outcome was change in SHAI score
from baseline to six months. Secondary outcomes were
change in the following self-reported measures from
baseline to 12 months:
 SHAI [21].
 7-item Generalised Anxiety Disorder for anxiety
(GAD-7) [25].
 15-item Patient Health Questionnaire for somatic
distress (PHQ-15) [26].
 9-item Patient Health Questionnaire for depression
(PHQ-9) [27].
 8-itemWork and Social Adjustment Scale for social
function (WSAS) [28].
 5-item quality of life on the EQ5D-5L including the
Visual Analogue Scale (VAS) [29].
 36-item Short Form Health Survey (SF-36) [30].
 Change in health care service utilisation established
through an adapted Client Service Receipt Inventory
(CSRI) [31].
At the baseline assessment only, participants were inter-
viewed using a standardised psychiatric interview [32] to
identify mental disorders. All baseline assessments were
conducted by te study researchers, either face-to-face or by
telephone, dependent on the participant’s preference. All
measures were selected because they have a history of rou-
tine use in settings within the UK National Health Service
(NHS), should RCBT be implemented into NHS practice.
Follow-up assessments were carried out at three, six, nine
and 12 months by telephone, email, videoconferencing,
post, or face-to-face, dependent on participant preference.
Health economics
Health economic analysis was conducted from a health
service and societal perspective. Resource use data were
collected at baseline, three, six, nine and 12 months
using the adapted CSRI, which included sections on out-
patient hospital appointments, inpatient stays, primary
and community care services, medicines and informal
care visits. For each type of health and social care ser-
vices use, an appropriate unit cost was identified and
valued using NHS reference costs from the reference
year 2017 [33] for both the RCBT intervention and TAU
groups. The intervention cost of using the technology
was further determined. Outcome was obtained in the
same periods using the EQ5D-5L [29] to calculate
quality-adjusted life-years (QALYs).
The incremental cost-effectiveness ratio (ICER) was
calculated for the RCBT intervention versus treatment
as usual:
ICER ¼ CostCBT−CostTAUð Þ= QALYCBT−QALYTAUð Þ
The threshold of £30,000 per QALY, set by the Na-
tional Institute for Health and Care Excellence (NICE)
[34] to assess the cost-effectiveness of RCBT. The RCBT
intervention is deemed to be cost-effective if ICERs fall
below this value.
Statistical analysis
The analysis was conducted on an intention-to-treat
basis. Multilevel modelling was performed to quantify
the treatment effects, with patient as a level 2 unit.
Time, treatment status and treatment × time interac-
tions and baseline measurements were included as co-
variates. Secondary outcomes were analysed in a similar
way. Missing values were explored and imputed under
the Missing At Random assumption [35]. Sensitivity
analysis was conducted with the same multilevel model
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on observed data to check the result’s robustness to
missingness. Stata 15 (StataCorp LLC, USA) and
Realcom-impute (University of Bristol, UK) software
were used for data analysis. More details can be found
on the trial statistical analysis plan [36].
Sample size and calculation
The results of the CHAMP study [15] showed that
the mean SHAI scores for CBT and TAU groups
were 24.9 (SD 4.2) and 25.1 (SD 4.5), respectively, at
baseline and 17.7 (SD 8.0) and 22.6 (SD 6.8), re-
spectively, at six months. Therefore, 114 participants
were required to detect such a difference in SHAI
score at six months to achieve 90% power at a
two-tailed significance level of 0.05, assuming equal
SD (8.0) for both groups and null correlation be-
tween baseline and follow-up measures for the pur-
pose of being conservative. After taking into account
a 20% loss to follow-up rate, a required sample size
of 144 was calculated. Stata 14 (StataCorp LLC,
USA) was used to run the power analysis. In Sep-
tember 2016, we observed that our follow-up rate
for the primary outcome measure was 75%. Thus, to
detect a difference, the sample size was increased to
152. Approval was obtained from the study sponsor,
an independent scientific committee and ethics com-
mittee to recruit additional participants, resulting in
a sample size of 156 participants.
Results
Of the 524 patients referred to the study and assessed
for eligibility between 19 November 2014 and 31 De-
cember 2016, 470 were eligible and 156 (33%) partici-
pants were recruited. Seventy-eight participants were
allocated to RCBT and 78 to TAU (Fig. 1). Researchers
were inadvertently un-blinded to 17 participants in the
RCBT group and one participant in the TAU group. No
Fig. 1 Consort diagram: participant flow into randomised controlled trial. *There was one randomization protocol violation. One participant who
was allocated into TAU by the randomisation system was accidentally sent the incorrect treatment allocation letter, resulting in them receiving
the RCBT therapy. This error was identified following the completion of treatment. The participant completed outcome data only at three
months. **There was an enrolment protocol violation. Two participants in the RCBT group did not meet the criteria of ≥18 on the SHAI. This error
was not identified until final analysis and as such both participants were included in the analysis
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treatment-related adverse events were reported in either
group.
Baseline characteristics for the two groups were simi-
lar (Table 1 and Additional file 1: Table S2). At baseline,
RCBT and TAU groups had median unscheduled
face-to-face healthcare consultations of 6.5 (IQR 3-12)
and 5 (IQR 3-10), respectively, in the preceding 12
months. Most participants (80%) were referred from pri-
mary care by their GP. Two-thirds were female and half
were under 35 years of age, although there was a wide
age range. At baseline, mean (SD) SHAI scores for the
RCBT and TAU arms were 27.31 (5.38) and 26.41 (5.13),
respectively. Table 1 shows that the mean (SD) scores at
baseline on the GAD-7 and the PHQ-9 were above clin-
ical cut-offs ( >8 and>10, respectively) for both groups
[21], indicating that clinically important comorbid gener-
alised anxiety and depression were typically present
alongside severe health anxiety. There were no clinically
important differences at baseline for any demographic or
clinical characteristic between the two treatment arms.
RCBT participants received a median of eight sessions
(range: 0–16) with 55 (71%) participants completing
therapy or attending ≥5 sessions. Forty-seven (60%) re-
ceived sessions via WebEx, 20 (25%) had sessions by
telephone and 11 (14%) received no sessions. Therapist
competency assessments using the CTSR indicated CBT
skill levels between the ‘competent’ and ‘proficient’ range
for all therapists, with an overall trend of improved skill
over time. Follow-up completion rates were similar be-
tween the two groups. In TAU and RCBT arms, 8
(10.2%) and 2 (2.6%, 7–12 months) participants, respect-
ively, received ≥2 sessions of any additional psycho-
logical treatment.
Table 2 and Fig. 2 show that participants in both arms
experienced a reduction in health anxiety, with participants
in the RCBT arm showing significantly greater reduction at
six months (mean change difference at six months –2.81
95% CI –5.11 to –0.50; P = 0.017), 9 and 12 months. Ana-
lysis confined only to participants with complete data at
baseline and six months showed nearly identical results
(Additional file 1: Figure S1 and Table 3). Recovery rates
on the SHAI are shown in Additional file 1: Table S4. Par-
ticipants in the RCBT arm also showed significantly greater
reductions in generalised anxiety (GAD-7) at six and 12
months, depression (PHQ-9) at 12 months and overall
health (VAS) at 12 months. No significant differences were
found on the PHQ-15 or WSAS between the two groups
at any time point. SF-36 results confirm improvements in
general health, with no differences in any other domain
(Additional file 1: Table S5).
Table 3 shows the total costs per patient over the
12-month follow-up. While there was no evidence of a
significant difference in cost per patient between the
RCBT intervention and TAU groups, there was a
significant reduction in the mean cost of inpatient hos-
pital use (P = 0.031).
Including the cost of providing RCBT, the mean over-
all cost saving per patient over 12 months with RCBT,
healthcare, medication, travel and informal care costs
was £1,064 (95% CI –£845–£2973, P = 0.269). The mean
cost of providing RCBT was calculated at £531.80 (95%
CI £466.80–£597.80).
QALYs were 0.66 and 0.59 for the intervention group
and the control group, respectively; this difference at 12
months was not significant (Table 2). However, the ICER
for QALYs was –£15,200 (the difference in cost, –
£1,064, divided by the difference in QALYs, 0·07), which
highlights additional expenditure to gain additional
QALYs. It is clear to see that the RCBT intervention rep-
resents lower cost and more QALYs; that is, the RCBT
intervention is in a position of strict dominance.
ICER ¼ ΔCost
ΔQALY
¼ CostCBT−CostTAU
QALYCBT−QALYTAU
¼
Á
E2197−
Á
E3261
0:66−0:59
¼ −
Á
E1; 064
0:07
¼ −ÁE15; 200
The uncertainty around the ICER was explored, given
that the ICER is based on sample means (Additional file 1:
Table S6). A negative ICER is nevertheless not easily inter-
pretable. Therefore, the net monetary benefit (NMB) was
calculated as:
incremental benefit  willingness‐to‐pay WTPð Þ thresholdð Þ
incremental cost
A positive NMB indicates that the intervention is
cost-effective compared to the alternative and vice versa.
We chose a WTP of £30,000, as recommended by NICE
guidelines [34]; the NMB at £30,000 is £3,164 with ob-
served values. Positive NMBs were generated using a
range of WTPs from £5,000 to £35,000, i.e. both
cost-saving and the cost-effectiveness are achieved by the
RCBT intervention compared to TAU (Table 4). Overall,
the RCBT intervention is in a position of strict domin-
ance, which means delivering the RCBT intervention
could reduce costs and demonstrate cost-effectiveness
compared to TAU using both the observed and multiple
imputation values.
Figure 3 illustrates a cost-effectiveness plane (CEP),
where the scatter of points is based on the results of a
non-parametric bootstrap analysis (5,000 replications)
on total costs and QALYs. The scatter of points is
mainly based in the southeast quadrant. In the southeast
quadrant, the CBT intervention is more effective and
less costly for health anxiety and thus dominates TAU.
For a given threshold of £30,000 by NICE, all points
below this threshold are deemed to be cost-effective
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Table 1 Baseline characteristics of participants
RCBT (n = 78) TAU (n = 78)
Age, median (range) years 31.12 (18.36–79.10) 33.28 (18.69–82.71)
Female, n (%) 56 (72) 52 (67)
Occupational status
Employed, n (%) 32 (41) 29 (37)
Student/training, n (%) 27 (35) 24 (31)
Homemaker, n (%) 0 2 (3)
Retired, n (%) 7 (9) 10 (13)
Unemployed, n (%) 12 (15) 13 (17)
Highest qualification
First degree or higher, n (%) 24 (31) 25 (32)
A-Level or other higher qualification, n (%) 28 (36) 30 (38)
O-Level/GCSE or other qualification, n (%) 19 (24) 20 (26)
No qualifications, n (%) 7 (9) 3 (4)
Marital status
Married/partner, n (%) 32 (41) 39 (50)
Single, n (%) 34 (45) 32 (41)
Divorced/widowed, n (%) 10 (13) 7 (9)
Ethnicity
White British, n (%)a 58 (74) 58 (74)
Referral type
GP, n (%) 63 (81) 62 (79)
Medical specialties, n (%) 9 (12) 7 (9)
Emergency department, n (%) 4 (5) 6 (8)
Walk-in centre, n (%) 2 (3) 3 (4)
Baseline scores
SHAI, mean (SD) 27.31 (5.38) 26.41 (5.13)
GAD7, mean (SD) 12.94 (5.49) 12.68 (6.13)
PHQ9, mean (SD) 13.35 (6.50) 13.12 (6.71)
PHQ15, mean (SD) 14.16 (5.63) 13.90 (6.45)
EQ5D-5L Utility Value, mean (SD) 0.61 (0.28) 0.60 (0.29)
VAS, mean (SD) 54.76 (21.72) 56.97 (22.58)
WSAS, mean (SD) 19.33 (11.40) 20.35 (10.54)
SF36 Physical functioning, mean (SD) 67.29 (30.39) 64.18 (32.04)
Role limitations – physical health, mean (SD) 29.81 (39.08) 28.90 (40.77)
Role limitations – emotional problems, mean (SD) 35.47 (42.07) 27.35 (41.17)
Energy/fatigue, mean (SD) 25.73 (20.39) 27.05 (22.48)
Emotional well-being, mean (SD) 40.92 (19.88) 42.54 (24.83)
Social functioning, mean (SD) 45.83 (29.10) 46.31 (30.82)
Pain, mean (SD) 47.47 (24.83) 41.38 (26.96)
General health, mean (SD) 28.27 (19.29) 36.25 (22.89)
Unscheduled care attendances in last 12 months, median (range) 6.5 (2.0–125.0) 5.0 (2.0–34.0)
afurther detail provided in Additional file 1
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because the CBT intervention is dominant in the south-
east quadrant.
Discussion
This study is the first to apply targeted, real-time, remotely
delivered CBT to address the clinical needs of repeat users
of unscheduled care with severe health anxiety and the re-
lated costs to health services. Results suggest that RCBT is
effective in reducing severe health anxiety at six months,
sustained to at least 12 months, while also reducing co-
morbid generalised anxiety and depression and improving
overall health in patients recruited from primary and sec-
ondary care services. The benefits are similar to those
achieved when offering face-to-face CBT for health anx-
iety with more selected groups such as hospital clinic at-
tenders [11, 13]. No differences were found between
Table 2 Multilevel modelling of changes in score from baseline to 12 month follow-up for remote cognitive behavioural therapy
(RCBT) intervention versus treatment as usual (TAU)
RCBT TAU Comparison
N Mean change from baseline (95% CI) N Mean change from baseline (95% CI) Difference (95% CI) P-value
SHAI
3 months 53 –6.08(–7.90 to –4.26) 48 –5.97(–7.97 to –3.97) –0.11(–2.82 to 2.60) 0.936
6 months 56 –9.48(–11.20 to –7.75) 56 –6.67(–8.30 to –5.04) –2.81(–5.11 to –0.50) 0.017
9 months 46 –9.58(–11.33 to –7.84) 50 –6.78(–8.43 to –5.12) –2.81(–5.11 to –0.50) 0.017
12 months 47 –10.60(–12.31 to –8.89) 47 –7.79(–9.43 to –6.16) –2.81(–5.11 to –0.50) 0.017
GAD 7
3 months 52 –3.69(–5.09 to –2.28) 48 –4.79(–6.17 to –3.41) 1.10(–0.84 to 3.05) 0.265
6 months 53 –6.22(–7.62 to –4.82) 55 –3.83(–5.21 to –2.44) –2.39(–4.40 to –0.39) 0.020
9 months 43 –5.37(–7.05 to –3.69) 48 –4.48(–5.97 to –2.99) –0.89(–3.00 to 1.23) 0.408
12 months 45 –6.68(–8.14 to –5.21) 46 –3.92(–5.40 to –2.45) –2.75(–4.82 to –0.68) 0.009
PHQ9
3 months 52 –3.24(–4.69 to –1.80) 47 –3.01(–4.38 to –1.64) –0.23(–2.15 to 1.68) 0.812
6 months 53 –4.67(–6.02 to –3.33) 55 –3.11(–4.46 to –1.76) 1.56(–3.45 to 0.33) 0.105
9 months 43 –4.41(–6.06 to –2.76) 48 –3.24(–4.78 to –1.69) –1.17(–3.18 to 0.83) 0.250
12 months 45 –5.05(–6.37 to –3.72 45 –2.69(–4.06 to –1.31) –2.36(–4.22 to –0.50) 0.013
PHQ15
3 months 52 –0.35(–1.58 to 0.88) 48 –1.68(–3.16 to –0.19) 1.33(–0.52 to 3.17) 0.157
6 months 54 –2.95(–4.11 to –1.78) 55 –1.62(–2.90 to –0.34) –1.33(–3.09 to 0.42) 0.137
9 months 45 –2.62(–4.19 to –1.04) 49 –2.20(–3.47 to –0.92) –0.42(–2.38 to 1.53) 0.669
12 months 46 –3.33(–4.62 to –2.04) 47 –1.77(–2.99 to –0.55) –1.57(–3.37 to 0.24) 0.089
EQ5D–5L (VAS)
3 months 52 8.74 (3.70 to 13.79) 47 2.80(–2.35 to 7.96) 5.94(–1.22 to 13.11) 0.103
6 months 54 13.66 (8.97 to 18.34) 55 11.10 (6.32 to 15.89) 2.56(–4.03 to 9.14) 0.446
9 months 45 10.24 (5.28 to 15.21) 49 2.92 (–2.06 to 7.90) 7.33(–0.02 to 14.67) 0.051
12 months 46 13.80 (8.90 to 18.71) 47 4.25 (–0.87 to 9.37) 9.56 (2.73 to 16.39) 0.006
WSAS
3 months 51 –4.45(–6.63 to –2.27) 48 –3.36(–5.61 to –1.10) –1.10(–4.07 to 1.87) 0.468
6 months 53 –7.52(–9.85 to –5.19) 55 –4.89(–7.03 to –2.75) –2.63(–5.72 to 0.45) 0.094
9 months 44 –7.31(–9.81 to –4.81) 56 –5.77(–8.15 to –3.39) –1.54(–4.99 to 1.90) 0.377
12 months 45 –7.89(–10.22 to –5.56) 56 –5.40(–7.79 to –3.01) –2.49(–5.73 to 0.75) 0.131
RCBT TAU Unadjusted difference in change
N Mean (SD) n Mean (SD) Mean (95% CI) (P-value)
QALYsa at 12 months 31 0.66 (0.22) 25 0.59 (0.31) 0.07 (0.07 to 0.21) (0.332)
aQALYs at 12 months is based on the complete dataset over the 12-month follow-ups
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participants in the RCBT or TAU groups in terms of ei-
ther somatic symptoms or work and social adjustment.
The RCBT intervention showed a position of strict eco-
nomic dominance, with a net monetary benefit of £3,164
per participant at a NICE-determined WTP threshold of
£30,000. Higher rates of recruitment (33% of those eli-
gible) than previous trials of psychological interventions in
frequently attending patients with health anxiety [11, 37]
suggest that the recruitment methods involving
non-stigmatising explanation and RCBT were acceptable.
Overall, our results suggest that targeted remote delivery
of CBT is a feasible, clinically effective and cost-saving
method of improving self-management in repeat users of
unscheduled care with severe health anxiety, with whom
health systems have previously struggled to engage.
Strengths
The study successfully recruited participants with high
levels of unscheduled healthcare use and severe health
anxiety; and those with clinical levels of comorbid depres-
sion, generalised anxiety, other bodily symptoms and poor
quality of life. The use of telephone and videoconferencing
interviews allowed participants of all backgrounds to be
engaged and recruited, particularly those who may have
been resistant or unable to access traditional mental
health services. Most participants were recruited through
Fig. 2 Mean (95% CI) change in 14-item Short Health Anxiety Inventory over 12 months remote cognitive behaviour therapy versus treatment
as usual
Table 3 Costs (£) per participant over 12-month follow-up period remote cognitive behaviour therapy versus treatment as usual
RCBT TAU Unadjusted difference in change
n Mean (SD) n Mean (SD) Mean (95% CI) (P-value)
CBT sessions 78 496 (294) 78 0 (0) 496 (431 to 562) (0.000)
Technology 78 35.8 (0) 78 0 (0) 35.8 (35.8 to 35.8) (N/A.)
Outpatient hospital visits 35 608 (871) 34 728 (706) –120 (–502 to 261) (0.531)
Inpatient hospital visits 38 22 (87) 37 258 (656) –236 (–450 to –23) (0.031)
Primary and community care 38 798 (838) 35 2066 (5224) –1,268 (–2,981 to 444) (0.144)
Travel 33 36 (46) 35 50 (109) –14 (–55 to 27) (0.495)
Medication 37 219 (402) 34 436 (1082) –217 (–597 to 163) (0.259)
Informal care 36 162 (536) 34 293 (1253) –130 (–586 to 325) (0.569)
Total cost 29 2197 (1048) 26 3261 (5010) –1064 (–2973 to 845) (0.269)
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usual care clinical encounters, particularly in primary care,
rather than large-scale screening procedures in general
hospital outpatient departments or direct public adverts
used in previous studies [9, 38–40]. The methods used
may be more easily incorporated into routine health sys-
tem procedures than has been typical.
This study confirms previous findings that similar
treatment effects achieved with face-to-face CBT can
also be realised using remotely delivered CBT [11–13].
Furthermore, the pragmatic, applied methods used in
this trial mean the results are potentially generalisable to
routine clinical practice in UK and other similar health
services.
The study further provides evidence that the user-design
and co-production approach we applied through networks
of practice [23] may have improved both engagement and
recruitment to the study as a whole and to RCBT in par-
ticular. A non-stigmatising explanation of health anxiety
and its effects, coupled with the delivery of RCBT, might be
utilised as a promising means of engaging repeat users of
unscheduled care with severe health anxiety into effective
treatment. Furthermore, the higher rates of recruitment
might also be attributed to the accessibility and
convenience of the RCBT intervention for each partici-
pant. The delivery methods also helped provide a com-
plex intervention over a large area, with a
comparatively small staff team, in terms of both con-
ducting the research and the RCBT.
Limitations
The requirement for only two unscheduled care appoint-
ments in the previous 12 months may appear arbitrary in
triaging patients at high risk of anxiety-related service use.
By not setting different thresholds for males and females,
we may have recruited a greater proportion of females
than males [41]. However, we recruited participants with
much higher baseline use of repeat unscheduled care in
the preceding year using this easily applied cut-off, sug-
gesting an appropriate set of inclusion criteria for clinical
use and that the gender composition of the sample would
not have been different if we had applied a higher cut-off
score.
We recognise that using digital technology in the
intervention group may have led to the selection of
younger participants, although participants up to the age
of 79 years utilised RCBT. However, use of the internet
Table 4 The net monetary benefit of remote cognitive behaviour therapy versus treatment as usual at various willingness to pay
(WTP) thresholds using EQ-5D-5L utilities
Net monetary benefit
WTP threshold £5,000 £10,000 £15,000 £20,000 £25,000 £30,000 £35,000
Observed values £1,414 £1,764 £2,114 £2,464 £2,814 £3,164 £3,514
Fig. 3 Plot of bootstrapped samples on the cost-effectiveness plan using EQ-5D-5L utilities
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does not necessarily mean that older participants could
not be recruited, nor that RCBT is ineffective in older
adults [38–40].
One of the main limitations of the trial was reduced
retention in follow-up. However, achieving 72% at six
months for our primary outcome is considerable, given
the complexities of this patient group, within routine
care across sectors. Lower rates of follow-up might be
expected in studies of harder-to-engage patients [42].
Similar results were obtained using only participants
who provided six months of follow-up data as when
using imputed data in the intention-to-treat analysis,
suggesting that the results are robust. A further limita-
tion is that lower follow-up rates at three, nine and 12
months than at six months mean there is less precision
concerning the treatment effects at these time points
than at six months. Further independent replication in a
larger sample would be desirable to test the robustness
of our findings. We did not inspect patients’ primary
care and general hospital records because self-report
may be more accurate in patients who frequently utilise
multiple sources of unscheduled care from different
agencies [37, 43].
Unlike some other internet and face-to-face delivered
CBT for health anxiety [15, 38–40], there was no differ-
ence in outcome at three months in our RCT. In the
current RCT, participants had previously received no
diagnosis or explanation for health anxiety, until, that is,
health anxiety was explained to all participants as part of
the informed consent process. As a result, there was a
substantial mean drop in the SHAI score of 6 points
from baseline in both treatment groups at three months,
with no benefit of RCBT over TAU emerging until six
months. Participants commented on the value of receiv-
ing an explanation of health anxiety to make sense of
their symptoms and, furthermore, around 10% of TAU
participants sought psychological treatment over 12
months. In contrast, participants in most previous RCTs
already had a diagnosis or understood they might have
health anxiety before participation.
Implications
Further research should explore whether the benefits of
RCBT in repeat users of unscheduled care with severe
health anxiety are maintained beyond 12 months [11]. Fur-
ther research is also required to directly compare the parity
of effectiveness of RCBT, face-to-face delivery and blended
approaches utilising both face-to-face and remote therap-
ies, according to participant and therapist preference.
At a time of financial restraint within health services,
this study presents a promising intervention that can
both improve the health of a hard-to-reach population
and reduce the cost to health services. We will separ-
ately report further qualitative data on the acceptability
of the intervention. The pragmatic design of this RCT
means procedures could be used in routine NHS care to
facilitate low-cost implementation. Such an approach re-
quires integration of care: participants are engaged
through primary care and some hospital departments
that provide continuing care, RCBT is delivered by psy-
chological treatment providers and the benefits to the
healthcare system are to the participant, their personal
support network (informal care), primary care and hos-
pital services.
For those who are unwilling or unable to engage in
face-to-face CBT for health anxiety in existing psycho-
logical treatment services, our methods of explanation
and remote delivery may provide a cheap, effective and
implementable method of delivering CBT to repeat users
of unscheduled care with high health anxiety, instead of
costly collusion of clinicians in a cycle of repeat investi-
gation, inter-specialist referral, additional medication
and clinician perpetuated follow-up [8, 10, 44].
Conclusion
Compared to usual care, RCBT may reduce health anx-
iety at six, nine and 12 months, and improve general
anxiety, depression and overall health at 12 months. It
may also reduce health and informal care costs in the
order of £1,000 per patient over 12 months in repeat
users of unscheduled care with severe health anxiety.
These patients have previously been difficult to engage
in psychological treatment, but in this trial, about
one-third were successfully engaged.
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